In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Highlighting PMS Symptom Reduction For Lybrel Contraceptive

Executive Summary

Wyeth is emphasizing improvement in menstrual cycle-related symptoms as a central benefit of its pending continuous-use regimen oral contraceptive Lybrel

You may also be interested in...



Seasonale not threatened by Librel

Wyeth's Librel, a "continuous-use" oral contraceptive in development, will not compete directly with Barr's 91-day regimen OC Seasonale, Barr says. "Our market research shows women prefer the quarterly product," CEO Bruce Downey said on a company conference call Nov. 4. However, "there is a minority of women who prefer a longer cycle, and that also shows up in the market research...Overall, incremental promotion of other extended regimen products will increase the category and it will benefit both Barr's products and Wyeth's products"...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Topics

UsernamePublicRestriction

Register

PS046505

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel